Martinelli Recalls 170,000 Apple Juice Bottles for Possible Toxin
By I. Edwards HealthDay Reporter
WEDNESDAY, April 30, 2025 — More than 170,000 bottles of Martinelli’s apple juice are being recalled due to possible contamination with a mold-related toxin, the U.S. Food and Drug Administration (FDA) said.
"Routine testing indicated that one lot of 10-ounce Martinelli’s Apple Juice glass bottles (in 4-packs only) produced in December 2023 may contain elevated levels of Patulin, a naturally occurring substance produced by molds that can grow in apples," a statement obtained by NBC News read.
The recall includes 7,234 cases of juice, each with 24 bottles. The affected bottles have a "best by" date of Dec. 5, 2026.
They are marked with UPC number 0 41244 04102 2, found below the barcode.
S. Martinelli & Co., based in Watsonville, California, issued the voluntary recall on March 18. The company said: "We hold ourselves to the highest standards of excellence, and the health and safety of our customers remains our greatest priority."
No illnesses have been reported so far, the company added.
The recalled apple juice was sold in 28 states: Alabama, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Texas, Utah, Virginia and Wisconsin.
Martinelli said it worked with stores that received the product to make sure any remaining bottles were removed from shelves.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-01 06:00
Read more

- Machine Learning Model Accurately Diagnoses Celiac Disease
- DDW: Systematic Program Increases Likelihood of Up-to-Date Colorectal Cancer Screening
- HHS Fires Team That Sets Federal Poverty Guidelines
- Some OB/GYNS Stay in States With Abortion Bans, Despite Legal Risks
- Fewer Americans Traveled for Abortions in 2024, Report Finds
- Globally, One in 13 Youth Experience Nocturnal Enuresis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions